Shake the Stigma of Neuropsychiatric Symptoms, Explained in 30 Seconds
Diseases and injuries that damage the brain can impact how we interact with the world and lead to significant and…
more.Published March 24, 2022
In June 2021, the Food and Drug Administration (FDA) approved a new treatment for Alzheimer’s disease–the first new therapy Alzheimer’s therapy in almost 20 years. But in January 2022, the Centers for Medicare and Medicaid Services (CMS) announced it has no plans to cover the treatment for most seniors. Even worse, CMS’ decision will extend to future FDA approved Alzheimer’s treatments in this class of drugs. So on March 15, 2022, patients and advocates gathered to make sure their voices were heard. This video shares highlights from the rally.
Diseases and injuries that damage the brain can impact how we interact with the world and lead to significant and…
more.Diseases and injuries that damage the brain can impact how we interact with the world and lead to significant and…
more.The pandemic has been stressful for everyone, especially older adults. Thankfully, COVID-19 vaccines have allowed us to reunite with…
more.The Alzheimer’s Disease Policy Task Force is an ad hoc coalition of patient, family caregiver, and professional organizations, working collectively to organize and educate the Alzheimer’s disease community and decisionmakers on the Food & Drug Administration’s (FDA) Accelerated Approval pathway, and the Centers for Medicare & Medicaid Services’ (CMS) coverage determination processes for amyloid-targeted monoclonal antibody therapies for the treatment of Alzheimer’s disease.